Abstract
Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
